Gwenn Hansen
Chief Scientific Officer · 10 filings · Latest: Oct 15, 2026
Nurix Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NRIX | Gwenn Hansen | Chief Scientific Officer | Oct 15, 2026 | Sale | $25.00 | 1,452 | $36.3K | 117,227 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Oct 15, 2026 | Option Exercise | $1.86 | 1,452 | $2.7K | 118,679 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Sep 1, 2026 | Sale | $25.47 | 1,452 | $37.0K | 117,227 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Sep 1, 2026 | Option Exercise | $1.86 | 1,452 | $2.7K | 118,679 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Aug 5, 2026 | Sale | $25.00 | 4,356 | $108.9K | 117,227 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Aug 5, 2026 | Option Exercise | $1.86 | 4,356 | $8.1K | 121,583 | |
NRIX | GWENN HANSEN | — | Aug 5, 2026 | Proposed Sale | $24.69 | 8,712 | $215.1K | — | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Aug 4, 2026 | Sale | $24.36 | 4,111 | $100.1K | 117,227 | |
NRIX | GWENN M HANSEN | — | Aug 4, 2026 | Proposed Sale | $23.22 | 4,111 | $95.5K | — | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Jul 30, 2026 | Sale | $23.38 | 3,847 | $90.0K | 121,338 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Jul 30, 2026 | Option Exercise | $0.00 | 10,180 | — | 125,185 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Jun 25, 2026 | Sale | $20.00 | 5,394 | $107.9K | 115,005 | |
NRIX | GWENN M HANSEN | — | Jun 25, 2026 | Proposed Sale | $19.30 | 5,394 | $104.1K | — | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Apr 30, 2026 | Sale | $16.65 | 3,214 | $53.5K | 120,399 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Apr 30, 2026 | Option Exercise | $0.00 | 8,608 | — | 123,613 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Feb 3, 2026 | Option Exercise | $0.84 | 31,333 | $26.3K | 115,005 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Jan 30, 2026 | Sale | $16.60 | 4,895 | $81.2K | 83,672 | |
NRIX | Gwenn Hansen | Chief Scientific Officer | Jan 30, 2026 | Option Exercise | $0.00 | 11,816 | — | 88,567 |